IntelGenx to file NDA amendment in first quarter

IntelGenx Technologies (TSX-V:IGX) has met with the FDA to discuss a complete response letter received in February about its new drug application for its antidepressant CPI-300 and expects to file an amendment to the NDA in the first quarter of 2011. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin [...]

IntelGenx to license anti-migraine film product

IntelGenx (TSX-V:IGX) has signed a binding term-sheet with closely held RedHill Biopharma of Israel to co-develop and license IntelGenx’s rapidly dissolving anti-migraine oral film product based on its VersaFilm technology. “We are excited to have concluded our first, of what we believe to be many future, thin film partnerships,” CEO Dr. Horst Zerbe said in [...]

Cannasat batting hot streak in its CNS turnaround

First time up to bat, Anthony Giovinazzo hit what he calls a triple.  He followed that up with a single.  Now, he’s looking to park one in the bleachers. Newly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer [...]